Expert Interview
Checking in with a prescriber of Amylyx's Relyvrio for the slowing of ALS progression.
Ticker(s): AMLXInstitution: Johns Hopkins Medicine
- Director of the Center For ALS Research and professor of neurology at Johns Hopkins Medicine.
- Manages ~650 patients with ALS and has prescribed Relyvrio to ~60 patients.
- Research interests include molecular mechanisms of selective neurodegeneration in motor neuron diseases, identification of novel drug or peptide therapeutics to delay or prevent motor neuron degeneration in ALS, and neuronal and non-neuronal stem cell therapies for ALS.
Roughly how many ALS patients have you prescribed Relyvrio to?
Added By: max_adminHow does Relyvrio compare to other treatment options available?
Added By: max_adminOverall what has the patient satisfaction been with this product?
Added By: max_adminIt’d be great to start with a practice overview for Dr. Rothstein.
It’d be helpful if you could walk us through
the typical ALS patient journey as it pertains to therapeutic interventions.
How you think about the therapies that you have at your disposal with riluzole,
edaravone, and relyvrio? What determines you prescribing one over another or
several agents in combination?
When did you begin prescribing relyvrio and what
has your experience with the drug looked like so far? Have you noticed any
significant changes in access / your utilization trends since you first started
using it?
Looks like you now have ~60 patients on Relyvrio. One year
from now do you see that number growing, staying the same shrinking?
What about your colleagues, do you think they’re
typically utilizing relyvrio in a similar way?
Added By: user02719249
Amylyx has phase 3 data upcoming next year. What
are your expectations for the trial and how do you see the outcome impacting
your utilization going forward?
Added By: user02719249
Any difference in insurance coverage between relyvrio and raticava?
Added By: user02719249Are you familiar with the TUDCA-ALS Italian study?
Added By: user02719249Are you familiar with masitinib?
Added By: user02719249Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
